Name: **Tami Barazani-Brutman, PhD**

Position: Head of the clinical studies team at the National Hemophilia Center and Thrombosis Institute ,Tel Hashomer, Israel.
Senior researcher at the and The Amalia Biron Research Institute, Tel Aviv University

Mail: Tami.Barazani-Brutman@sheba.health.gov.il; tamibrut@yahoo.com

Education

July 2021	ICH GCP (R2) (online training)
October 2018	ICH GCP (R2) (online training)
June 2017	GCP refreshment (online training)
Feb 2012	GCP and study management training Sheba Medical Centre, Ramat Gan, Israel
Feb 2010	GCP (Good Clinical Practice) training Sheba Medical Centre, Ramat Gan, Israel
2005-2009	Bar-Ilan University, Ramat-Gan , Israel, **Faculty of Life Sciences. Ph.D. Biology** Research founded by "Milgat Nasi", a scholarship awarded to excelling students. Advisor: Prof. Sanford Sampson & Prof. Chaya Brodie
2002-2004	Bar-Ilan University, Ramat-Gan , Israel, **Faculty of Life Sciences. M.Sc. Biology**, graduated with high honors Advisor: Prof. Sanford Sampson.
Jan-June 2002	Dundee College, Dundee, Scotland, U.K. Professional English for foreign students
1997-2001	Bar-Ilan University ,Ramat-Gan , Israel, **Faculty of Life Sciences . B.Sc. Biology**, graduated with honors **Computer Science Department. B.Sc. Computer Science (Minor)**

Work Experience

2019-Present	Principal Investigator in “ALEH” - Israeli Hemophilia Association
2017-Present	Invited speaker in clinical reaserch meetings and a member in international advisory board of nurses and study coordinators.
July 2009-Present	The National Hemophilia Center & Institute of Thrombosis Sheba Medical Center, Tel-Hashomer, Israel Head of clinical studies. Responsibilities: supervision of study conduct (studies sponsored by pharmacutical companies and Investigator initiated studies run

	simultaneously in our site), IRB submission, interaction and negotiation with pharmaceutical companies, preparation of site for audits and inspections, building internal budgets, involvement in writing grant proposals and publications
2006 - 2009	Bar-Ilan University, Ramat-Gan , Israel Organizer and Instructor in Biology lab for overseas student program. Given in the english language
2003 - 2009	Bar-Ilan University, Ramat-Gan , Israel Instructor of the courses ″computer aided problem solving″.
1997-2001	Sela Group, IT training, Bney-Brak, Israel Lecturer in Boolean Algebra, C programming and Unix
Miscellaneous	Fluent Hebrew, fluent English and spoken Russian
Military Service	1995-1997 Intelligence of the Air Force

Publications

Barg AA, Levy-Mendelovich S. Budnik I,Mandel-Shorer N, Dardik R, Avishai E, ***Brutman-Barazani T,*** *Dvir Ifrah A, Oren-Malek L, Yacobovich J, Gilad O, Nakav S, Fruchtman Y, Revel-Vilk S, Miskin H, Kenet T.* Pediatric severe factor XI deficiency: A multicenter study. Pediatric Blood & Cancer 26 Dec 2021. doi.org/10.1002/pbc.29545

Levy-Mendelovich S,* ***Brutman-Barazani T*****, Budnik I, Avishai E, Barg AA, Levy T, Misgav M, Livnat T, Kenet G.*Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab. J Clin Med. 2021 Sep 22;10(19):4303. doi: 10.3390/jcm10194303.
**Equal share*

Barg AA, Budnik I, Avishai E, ***Brutman-Barazani T****, Bashari D, Misgav M, Lubetsky A, Kuperman AA, Livnat T, Kenet G*. Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring. Haemophilia. 2021 May;27(3):383-391. doi: 10.1111/hae.14318. Epub 2021 Apr 23.

*Misgav,Mudi** ***Brutman Barazani T****, Tami; Budnik, Ivan; Einat, avishai; Schapiro, Jonathan; Bashari, Dalia; Barg, Assaf; Livnat, Tami; Kenet, Gili* Emicizumab prophylaxis in HA patients older than 50 years, with cardiovascular risk factors- real world data. paper HAE-00483-2020.R1 - Haemophilia Jan 2021
**Equal share*

Barg AA, Avishai E, Budnik I, ***Brutman TB****, Tamarin I, Dardik R, Bashari D, Misgav M, Lubetsky A, Lalezari S, Livnat T, Kenet G*. The potential role of emicizumab prophylaxis in severe von Willebrand disease. Blood Cells Mol Dis. 2021 Mar;87:102530. doi: 10.1016/j.bcmd.2020.102530. Epub 2020 Dec 8.

Barg AA, Livnat T, Budnik I, Avishai E, ***Brutman-Barazani T****, Tamarin I, Bashari D, Misgav M, Kenet G.*Emicizumab treatment and monitoring in a paediatric cohort: real-world data.
Br J Haematol. 2020 Oct;191(2):282-290. doi: 10.1111/bjh.16964. Epub 2020 Jul 12.
Levy-Mendelovich S, Livnat T, Barg AA, Kidon M, ***Brutman-Barazani T****, Kenet G.*
Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions.
Blood Cells Mol Dis. 2020 Feb; Epub 2019 Oct 20.

Barg AA, Avishai E, Budnik I, Levy-Mendelovich S, ***Barazani TB****, Kenet G, Livnat T.*

Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
Pediatr Blood Cancer. 2019 Nov; 66 (11):

Barg AA, Dardik R, Levy-Mendelovich S, ***Brutman Barazani T****, Bashari D, Kenet G.*
Hemophilia – A royal disease in the holy land.
Harefuah. 2019 Mar;158(3):173-175.

Zilinsky I, ***Brutman Barazani T****, Visentin D, Ahuja K, Martinowitz U, Haik J*
Subcutaneous Injection of Tranexamic Acid to Reduce Bleeding During Dermatologic Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Dermatol Surg. 2019 Jan 11.

Kesten D, Horovitz-Fried M, ***Brutman-Barazani T****, Sanford R.*
Insulin-Induced Translocation of IR to the Nucleus In Insulin Responsive Cells Requires a Nuclear Translocation Sequence. Biochim Biophys Acta. 2018 Apr; 1865 (4):551-559

Sagiv O, Rosenfeld E, Kalderon E, ***Barazani Brutman T****, Zloto O, Martinowitz U, Ben Simon GJ, Zilinsky I.*
Subcutaneous tranexamic acid in upper eyelid blepharoplasty: a prospective randomized pilot study. Can J Ophthalmol. 2018 Dec; 53(6):600-604. doi: 10.1016/j.jcjo.2018.01.006. Epub 2018 Mar 27.

Livnat T, Budnik I, Levy-Mendelovich S, Avishai E, Misgav M, Barg AA, Lubetsky A, ***Brutman-Barazani T****, Kenet G.* Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors. Blood Cells Mol Dis. 2017 Jun.

Misgav M, Lubetszki A, ***Brutman-Barazani T****, Martinowitz U, Kenet G.* The hemostatic efficacy of chitosan-pads in hemodialysis patients with significant bleeding tendency.
J Vasc Access. 2017 May 15;18(3):220-224

Zilinsky I, ***Brutman Barazani T****, Shenkman B, Weisman O, Farber N, Martinowitz U.* Topical Hemostatic-Anesthetic Solution to Reduce Bleeding During Mohs Micrographic Surgery: A Case Control Study. J Drugs Dermatol. 2016 Jul 1; 15(7):851-5.

Martinowitz U, Lissitchkov T, Lubetsky A, Jotov G, ***Barazani-Brutman T****, Voigt C, Jacobs I3, Wuerfel T, Santagostino E.* Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
Haemophilia. 2015 Nov; 21(6):784-90.

Livnat T, Martinowitz U, Azar-Avivi S, Zivelin A, ***Brutman-Barazani T,*** *Lubetsky A, Kenet G.*Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
Haemophilia. 2013 Sep; 19(5):782-9.

Brutman-Barazani T*, Horovitz-Fried M, Aga-Mizrachi S, Brand C, Brodie C, Rosa J, Sampson SR.* Protein kinase Cδ but not PKCα is involved in insulin-induced glucose metabolism in hepatocytes. J Cell Biochem. 2012 Jan 23.

Brand C., Horovitz-Fried M., Inbar A, ***Brutman-Barazani T****., Brodie C.,and Sampson R. S..* Insulin stimulation of PKCδ triggers its rapid degradation via the ubiquitin-proteasome pathway. Biochim Biophys Acta. 2010 Nov; 1803(11):1265-75.

Smirin P, Taler D, Abitbol G, ***Brutman-Barazani T****, Kerem Z, Sampson SR,* Rosenzweig T. Sarcopoterium spinosum extract as an antidiabetic agent: in vitro and in vivo study. J Ethnopharmacol. 2010 May 4;129(1):10-7.

*Jacob AI, Horovitz-Fried M, Aga-Mizrachi S, **Brutman-Barazani T**, Okhrimenko H, Zick Y, Brodie C, Sampson SR.* The regulatory domain of protein kinase C delta positively regulates insulin receptor signaling. J Mol Endocrinol. 2010 Mar;44(3):155-69.

Horovitz-Fried M, **Brutman-Barazani T***, Kesten D, Sampson SR.*
Insulin Increases Nuclear Protein Kinase Cδ in L6 Skeletal Muscle Cells.
Endocrinology. 2008 Apr;149(4):1718-27.
** Equal contribution*

*Aga-Mizrachi S, **Brutman-Barazani T**, Jacob AI, Bak A, Elson A, Sampson SR.* Cytosolic protein tyrosine phosphatase-epsilon is a negative regulator of insulin signaling in skeletal muscle. Endocrinology. 2008 Feb;149(2):605-14.

Clinical Studies

During the last years I have been involved in dozens of audits and 3 FDA inspection with successful results (NAI).

1. A Multi-Centre, Open-Label, Non-Controlled Trial on Efficacy and Safety of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Previously Treated Subjects with Hemophilia A (NN7008-3543).

2. Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects with Hemophilia A (NN7008-3568).

3. Randomized, Active-Controlled, Double-Blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-Week Prophylaxis Treatment With BAY 79-4980 Compared to Three Times-Per-Week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A (BAY 79-4980).

4. Phase I/II/III Pharmacokinetic and Outcome. Study of Inspiration's Recombinant Factor IX Product, IB1001, in Subjects with Hemophilia B.

5. Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism BAY 59-7939. 12892

6. A Phase I/IIa, Open-Label, Crossover, Dose-Escalation, and Multi-Center Study To Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc in Previously Treated Patients with Severe Hemophilia A, Protocol 998HA101.

7. A-LONG: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A, Protocol 998HA301

8. An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A. Biogen Idec Protocol 8HA01EXT

9. An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B, Study Number: CSL654_2001.

10. A Phase I/II Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B, Study Number: CSL654_2004

11. A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B Study Number: CSL654_3001
12. A Phase III Open-label, Multicenter, Pharmacokinetics, Safety, and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Children with Hemophilia B. CSL654_3002.

13. A multi-center Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy. BAY 81-8973 / 13400.

14. A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A. NN7088-3859.

15. Efficacy and Safety of NNC 0129-0000-1003 during Surgical Procedures in Patients with Haemophilia A. NN7088-3860.

16. A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A. NN7088-3885.

17. A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in Severe Hemophilia A. BAY 94-9027 / 13024

18. A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children (age <12 years) with severe hemophilia A. BAY 94-9027 / 15912.

19. A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A.

20. A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B. CSL654_3003

21. 30-day, open-label, active-controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis.14373

22. Multicenter, open-label, active-controlled, randomized, multiple dose study to evaluate safety and efficacy of rivaroxaban oral suspension and film coated tablets in paediatric subjects from birth to less than 18 years of age who have acute venous thromboembolism. 14372

23. 4-week, open label, multiple dose study of the safety and the pharmacokinetic and pharmacodynamic properties of the oral direct factor Xa inhibitor rivaroxaban in pediatric subjects aged =>6 months to <6 years with venous thromboembolism. 14374

24. A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.

25. Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B. NN7999-3895.

26. Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A. NN7088-3908.

27. A Phase 1/2A, Open-Label, Multicenter, Dose Escalation Study to assess the Safety, Pharmacokinetics and Pharmacodynamics Profile of a Long-Actnf Recombinant Factor VIIA (MOD-5014) in Adult Men with Hemophilia A or B. CP-5-001.

28. "explorerTM3" A multi-centre, randomised, placebo controlled, double blinded, multiple dose trial investigating safety, pharmacokinetics and pharmacodynamics of concizumab administered subcutaneously to haemophilia A subjects. NN7415-4159.

29. A Phase 3, Open-Label, Randomized, Multicenter, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efiicacy and Safety of Edoxaban with Standard of Care Anticoagulant Therapy in Pediatric Subjects from Birth to less than 18 Years of Age with Confirmed Venous Throboembolism (VTE). Protocol Number: DU176b-D-U312.

30. Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A. Protocol Number: 261303.

31. A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors. NN7415-4310.

32. A single-arm, multicenter phase IIB clinical trial to evaluate the safety and tolerability of prophylactic Emicizumab in Hemophilia A patients with inhibitors. Protocol Number: MO39129.

33. A Prospective Non-Interventional Study of Bleeding Episodes, Factor VIII Infusions, and Patient-Reported Outcomes in Individuals with Severe Hemophilia A. Protocol Number:270-902
34. Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions. Protocol Number:270-301.

35. A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemophilia A Patients with Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions. Protocol Number: 270-302.

36. ATLAS-PPX: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in patients with hemophilia A and B with inhibitory antibodies to factor VIII or IX previously receiving bypassing agent prophylaxis. Protocol Number: LN-AT3SC-009.

37. ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX. Protocol Number: ALN-AT3SC-004.

38. ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX. Protocol Number: ALN-AT3SC-003.

39. ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX Protocol number: LTE15174

40. An open Label, non-investigational product, Multi-Center, lead in study to evaluate at least 6 months of prospective efficacy and selected safety data of Factor IX (FIX) prophylaxis replacement therapy in the usual care setting of moderately severe to severe adult Hemophilia B subjects (FIX.≤2%) who are negative for neutralizing antibodies (NAB) to adeno-associated virus vector (AAV)-SPARK100. Protocol Number: C0371004.

41. A Phase 1 Study to assess pharmacokinetics and pharmacodynamics following administration of BAY1093884 in patients with severe hemophilia. Protocol number: 19592.